Details for Patent: 9,439,906

Which drugs does patent 9,439,906 protect, and when does it expire?

Patent 9,439,906 protects INVEGA SUSTENNA and is included in one NDA.

This patent has thirty-six patent family members in twenty-seven countries.

Summary for Patent: 9,439,906

Title:	Dosing regimen associated with long acting injectable paliperidone esters
Abstract:	The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations.
Inventor(s):	Vermeulen; An (Beerse, BE), Wouters; Alfons (Beerse, BE)
Assignee:	Janssen Pharmaceutica NV (BE)
Application Number:	12/337,144
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,439,906
Patent Claim Types: see list of patent claims	Use; Formulation; Composition;

Drugs Protected by US Patent 9,439,906

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-001	Jul 31, 2009		RX	Yes	No						TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-001	Jul 31, 2009		RX	Yes	No						TREATMENT OF SCHIZOPHRENIA
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-001	Jul 31, 2009		RX	Yes	No						DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-001	Jul 31, 2009		RX	Yes	No						DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-002	Jul 31, 2009		RX	Yes	No						TREATMENT OF SCHIZOPHRENIA
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-002	Jul 31, 2009		RX	Yes	No						TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS

International Family Members for US Patent 9,439,906

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2008340101
Australia	2015200801
Brazil	PI0821408
Canada	2655335
China	101932327
China	105560176